FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080309100> ?p ?o ?g. }

• W2080309100 endingPage "135" @default.
• W2080309100 startingPage "126" @default.
• W2080309100 abstract "Objective. The purpose of this prospective study was to investigate the toxicity and efficacy of integrating extended-field para-aortic and pelvic external radiation, high-dose-rate intracavity brachytherapy, and concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer. Method. A phase I/II study was performed from 1998 to 2003 including sixty-three patients with both clinical FIGO and MRI/CT-based TNM stage IIB-IVA cervical cancer. Patients were treated with extended-field external radiation to the para-aortic and pelvic regions with 45 Gy in 25 fractions, and an additional boost to the gross nodes to 50.4 Gy and the parametrium to 59.4 Gy. Patients also received a high-dose-rate (HDR) intracavity brachytherapy with doses of 22–31 Gy to point A in 4–6 fractions. Concurrently, two cycles of cisplatin (50–80 mg/m2) were administered in weeks 1 and 5 during radiotherapy, as well as two cycles of cisplatin (60–80 mg/m2) for 1 day and 5-fluorouracil (600–800 mg/m2) for 4 days at 1 and 2 months after completion of radiotherapy. The treatment-related acute and late side effects were evaluated using RTOG criteria, and the disease control and survival rate were calculated using the Kaplan–Meier method. The median follow-up interval was 36 months. Results. All sixty-three patients completed the planned extended-field radiotherapy and high-dose-rate brachytherapy with 2 concurrent cycles of cisplatin. Fifty-eight (92%) patients received 2 cycles of the post-radiation adjuvant chemotherapy of cisplatin and 5-fluorouracil. RTOG grade III acute toxicity was gastrointestinal (2%) and hematological (10%). No patient had grade IV acute toxicity. Late grades III–IV morbidity actuarial risk of 6% at 6.5 years primarily involved the injuries to the bowels requiring surgical intervention for intestinal obstruction or fistula formation. Initial sites of recurrence were locoregional failure alone (pelvic and para-aortic regions within the radiation field), 3%; distant metastases only, 8%; and locoregional failure plus distant metastases, 8%. The observed rates at 3-year and 5-year of locoregional control, freedom from distant metastasis, and overall survival were 86% and 86%, 81% and 81%, and 81% and 77%, respectively. Conclusion. Incorporating HDR brachytherapy into a regimen including concurrent chemotherapy and extended radiation appears safe and effective." @default.
• W2080309100 created "2016-06-24" @default.
• W2080309100 creator A5016539263 @default.
• W2080309100 creator A5022317854 @default.
• W2080309100 creator A5025970940 @default.
• W2080309100 creator A5026388371 @default.
• W2080309100 creator A5052709196 @default.
• W2080309100 creator A5052942396 @default.
• W2080309100 creator A5059276032 @default.
• W2080309100 creator A5059771210 @default.
• W2080309100 creator A5069135532 @default.
• W2080309100 creator A5091901983 @default.
• W2080309100 date "2005-04-01" @default.
• W2080309100 modified "2023-10-16" @default.
• W2080309100 title "Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study" @default.
• W2080309100 cites W1513851013 @default.
• W2080309100 cites W1935824237 @default.
• W2080309100 cites W1973600557 @default.
• W2080309100 cites W1978764072 @default.
• W2080309100 cites W1982035273 @default.
• W2080309100 cites W1996509646 @default.
• W2080309100 cites W1998097361 @default.
• W2080309100 cites W1999954493 @default.
• W2080309100 cites W2008594609 @default.
• W2080309100 cites W2010347175 @default.
• W2080309100 cites W2020080153 @default.
• W2080309100 cites W2030607437 @default.
• W2080309100 cites W2041798479 @default.
• W2080309100 cites W2050128939 @default.
• W2080309100 cites W2066840748 @default.
• W2080309100 cites W2074014374 @default.
• W2080309100 cites W2086797699 @default.
• W2080309100 cites W2090186293 @default.
• W2080309100 cites W2093739424 @default.
• W2080309100 cites W2095815220 @default.
• W2080309100 cites W2097945491 @default.
• W2080309100 cites W2120405223 @default.
• W2080309100 cites W2121641562 @default.
• W2080309100 cites W2134890587 @default.
• W2080309100 cites W2137197268 @default.
• W2080309100 cites W2137751332 @default.
• W2080309100 cites W2157719711 @default.
• W2080309100 cites W2167277032 @default.
• W2080309100 cites W2314753133 @default.
• W2080309100 cites W2324392028 @default.
• W2080309100 cites W2328935341 @default.
• W2080309100 cites W4230938544 @default.
• W2080309100 cites W4235126653 @default.
• W2080309100 cites W4239405706 @default.
• W2080309100 doi "https://doi.org/10.1016/j.ygyno.2004.12.039" @default.
• W2080309100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15790448" @default.
• W2080309100 hasPublicationYear "2005" @default.
• W2080309100 type Work @default.
• W2080309100 sameAs 2080309100 @default.
• W2080309100 citedByCount "54" @default.
• W2080309100 countsByYear W20803091002012 @default.
• W2080309100 countsByYear W20803091002013 @default.
• W2080309100 countsByYear W20803091002014 @default.
• W2080309100 countsByYear W20803091002015 @default.
• W2080309100 countsByYear W20803091002016 @default.
• W2080309100 countsByYear W20803091002017 @default.
• W2080309100 countsByYear W20803091002018 @default.
• W2080309100 countsByYear W20803091002019 @default.
• W2080309100 countsByYear W20803091002020 @default.
• W2080309100 countsByYear W20803091002021 @default.
• W2080309100 countsByYear W20803091002022 @default.
• W2080309100 countsByYear W20803091002023 @default.
• W2080309100 crossrefType "journal-article" @default.
• W2080309100 hasAuthorship W2080309100A5016539263 @default.
• W2080309100 hasAuthorship W2080309100A5022317854 @default.
• W2080309100 hasAuthorship W2080309100A5025970940 @default.
• W2080309100 hasAuthorship W2080309100A5026388371 @default.
• W2080309100 hasAuthorship W2080309100A5052709196 @default.
• W2080309100 hasAuthorship W2080309100A5052942396 @default.
• W2080309100 hasAuthorship W2080309100A5059276032 @default.
• W2080309100 hasAuthorship W2080309100A5059771210 @default.
• W2080309100 hasAuthorship W2080309100A5069135532 @default.
• W2080309100 hasAuthorship W2080309100A5091901983 @default.
• W2080309100 hasConcept C121608353 @default.
• W2080309100 hasConcept C126322002 @default.
• W2080309100 hasConcept C126838900 @default.
• W2080309100 hasConcept C126894567 @default.
• W2080309100 hasConcept C143998085 @default.
• W2080309100 hasConcept C203092338 @default.
• W2080309100 hasConcept C2776694085 @default.
• W2080309100 hasConcept C2777416452 @default.
• W2080309100 hasConcept C2778220009 @default.
• W2080309100 hasConcept C2778239845 @default.
• W2080309100 hasConcept C2779808985 @default.
• W2080309100 hasConcept C2989005 @default.
• W2080309100 hasConcept C31760486 @default.
• W2080309100 hasConcept C509974204 @default.
• W2080309100 hasConcept C535046627 @default.
• W2080309100 hasConcept C71924100 @default.
• W2080309100 hasConceptScore W2080309100C121608353 @default.
• W2080309100 hasConceptScore W2080309100C126322002 @default.
• W2080309100 hasConceptScore W2080309100C126838900 @default.
• W2080309100 hasConceptScore W2080309100C126894567 @default.

• next